NasdaqGM:SUPNPharmaceuticals
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Q1 Beat And Reaffirmed Guidance
Supernus Pharmaceuticals (SUPN) is back in focus after reporting first quarter 2026 results that topped Wall Street earnings and revenue expectations, with Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO playing key roles.
See our latest analysis for Supernus Pharmaceuticals.
Supernus Pharmaceuticals’ share price has been broadly steady in recent months, with a 2.7% 1 month share price decline and a roughly flat 90 day move. However, a 59.0% 1 year total shareholder return points to strong longer term...